vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Liberty Broadband Corp (LBRDA). Click either name above to swap in a different company.

Liberty Broadband Corp is the larger business by last-quarter revenue ($261.0M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 6.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 4.3%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Liberty Global Ltd. is a British-Dutch-American multinational telecommunications company domiciled in Bermuda, with headquarters in London, Amsterdam and Denver. Its respective legal names are Liberty Global Holdings Limited (UK), Liberty Global B.V. (Netherlands) and Liberty Global, Inc., with the first of these being publicly traded. It was formed in 2005 by the merger of the international arm of Liberty Media and UnitedGlobalCom (UGC).

ESPR vs LBRDA — Head-to-Head

Bigger by revenue
LBRDA
LBRDA
1.5× larger
LBRDA
$261.0M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+137.6% gap
ESPR
143.7%
6.1%
LBRDA
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
4.3%
LBRDA

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
ESPR
ESPR
LBRDA
LBRDA
Revenue
$168.4M
$261.0M
Net Profit
$383.0M
Gross Margin
Operating Margin
50.6%
15.7%
Net Margin
146.7%
Revenue YoY
143.7%
6.1%
Net Profit YoY
96.4%
EPS (diluted)
$0.32
$2.68

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
LBRDA
LBRDA
Q4 25
$168.4M
Q3 25
$87.3M
Q2 25
$82.4M
$261.0M
Q1 25
$65.0M
$266.0M
Q4 24
$69.1M
$263.0M
Q3 24
$51.6M
$262.0M
Q2 24
$73.8M
$246.0M
Q1 24
$137.7M
$245.0M
Net Profit
ESPR
ESPR
LBRDA
LBRDA
Q4 25
Q3 25
$-31.3M
Q2 25
$-12.7M
$383.0M
Q1 25
$-40.5M
$268.0M
Q4 24
$291.0M
Q3 24
$-29.5M
$142.0M
Q2 24
$-61.9M
$195.0M
Q1 24
$61.0M
$241.0M
Operating Margin
ESPR
ESPR
LBRDA
LBRDA
Q4 25
50.6%
Q3 25
-11.4%
Q2 25
8.6%
15.7%
Q1 25
-34.0%
16.2%
Q4 24
-6.4%
4.9%
Q3 24
-31.0%
11.5%
Q2 24
3.5%
8.5%
Q1 24
52.5%
11.4%
Net Margin
ESPR
ESPR
LBRDA
LBRDA
Q4 25
Q3 25
-35.9%
Q2 25
-15.4%
146.7%
Q1 25
-62.2%
100.8%
Q4 24
110.6%
Q3 24
-57.2%
54.2%
Q2 24
-83.9%
79.3%
Q1 24
44.3%
98.4%
EPS (diluted)
ESPR
ESPR
LBRDA
LBRDA
Q4 25
$0.32
Q3 25
$-0.16
Q2 25
$-0.06
$2.68
Q1 25
$-0.21
$1.87
Q4 24
$-0.14
$2.04
Q3 24
$-0.15
$0.99
Q2 24
$-0.33
$1.36
Q1 24
$0.34
$1.69

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
LBRDA
LBRDA
Cash + ST InvestmentsLiquidity on hand
$167.9M
$180.0M
Total DebtLower is stronger
$3.1B
Stockholders' EquityBook value
$-302.0M
$10.4B
Total Assets
$465.9M
$16.6B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
LBRDA
LBRDA
Q4 25
$167.9M
Q3 25
$92.4M
Q2 25
$86.1M
$180.0M
Q1 25
$114.6M
$226.0M
Q4 24
$144.8M
$163.0M
Q3 24
$144.7M
$168.0M
Q2 24
$189.3M
$73.0M
Q1 24
$226.6M
$108.0M
Total Debt
ESPR
ESPR
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
$3.1B
Q1 25
$3.8B
Q4 24
$3.8B
Q3 24
$3.7B
Q2 24
$3.6B
Q1 24
$3.6B
Stockholders' Equity
ESPR
ESPR
LBRDA
LBRDA
Q4 25
$-302.0M
Q3 25
$-451.4M
Q2 25
$-433.5M
$10.4B
Q1 25
$-426.2M
$10.1B
Q4 24
$-388.7M
$9.8B
Q3 24
$-370.2M
$9.5B
Q2 24
$-344.2M
$9.3B
Q1 24
$-294.3M
$9.1B
Total Assets
ESPR
ESPR
LBRDA
LBRDA
Q4 25
$465.9M
Q3 25
$364.0M
Q2 25
$347.1M
$16.6B
Q1 25
$324.0M
$17.0B
Q4 24
$343.8M
$16.7B
Q3 24
$314.1M
$16.3B
Q2 24
$352.3M
$16.0B
Q1 24
$373.1M
$15.7B
Debt / Equity
ESPR
ESPR
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
0.30×
Q1 25
0.38×
Q4 24
0.38×
Q3 24
0.39×
Q2 24
0.39×
Q1 24
0.40×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
LBRDA
LBRDA
Operating Cash FlowLast quarter
$45.2M
$91.0M
Free Cash FlowOCF − Capex
$37.0M
FCF MarginFCF / Revenue
14.2%
Capex IntensityCapex / Revenue
0.0%
20.7%
Cash ConversionOCF / Net Profit
0.24×
TTM Free Cash FlowTrailing 4 quarters
$-49.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
LBRDA
LBRDA
Q4 25
$45.2M
Q3 25
$-4.3M
Q2 25
$-31.4M
$91.0M
Q1 25
$-22.6M
$78.0M
Q4 24
$-35.0M
$1.0M
Q3 24
$-35.3M
$24.0M
Q2 24
$-7.2M
$27.0M
Q1 24
$53.8M
$52.0M
Free Cash Flow
ESPR
ESPR
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
$37.0M
Q1 25
$13.0M
Q4 24
$-63.0M
Q3 24
$-35.5M
$-36.0M
Q2 24
$-7.3M
$-35.0M
Q1 24
$53.8M
$-9.0M
FCF Margin
ESPR
ESPR
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
14.2%
Q1 25
4.9%
Q4 24
-24.0%
Q3 24
-68.7%
-13.7%
Q2 24
-9.9%
-14.2%
Q1 24
39.0%
-3.7%
Capex Intensity
ESPR
ESPR
LBRDA
LBRDA
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
20.7%
Q1 25
0.0%
24.4%
Q4 24
0.0%
24.3%
Q3 24
0.3%
22.9%
Q2 24
0.1%
25.2%
Q1 24
0.1%
24.9%
Cash Conversion
ESPR
ESPR
LBRDA
LBRDA
Q4 25
Q3 25
Q2 25
0.24×
Q1 25
0.29×
Q4 24
0.00×
Q3 24
0.17×
Q2 24
0.14×
Q1 24
0.88×
0.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

LBRDA
LBRDA

Segment breakdown not available.

Related Comparisons